Once the AR is activated, the SPDEF expression level is enhanced, and it is translocated to nuclei to suppress CCL2 expression after binding to the CCL2 promoter region, consequently inhibiting the EMT in PCa. The gene discussed is SPDEF; the disease is posterior cortical atrophy.